Retatrutide Phase 2 Study Investigates Weight Loss in Obesity and Overweight
Background
Obesity and being overweight are major global health challenges, often leading to severe weight-related comorbidities such as cardiovascular disease and metabolic dysfunction. Current treatments offer varying degrees of efficacy, highlighting a continuous need for more potent and well-tolerated therapeutic options. This Phase 2 study aims to evaluate the efficacy and safety of once-weekly subcutaneous LY3437943 (Retatrutide) at multiple maintenance dose levels in adults with obesity or overweight without type 2 diabetes.
Results
As this is a recruiting study (NCT07467447) with an estimated completion date of 2028-02-17, specific efficacy and safety results are not yet available. However, the study is designed to rigorously evaluate the potential of LY3437943 to induce significant weight loss. > The primary efficacy evaluation will be the percent change in body weight at Week 24 compared to the placebo group. Secondary assessments will track additional weight, anthropometric (body measurements), and safety data through Week 48. The study will also compare the tolerability of different dose escalation schedules for the 4 mg and 8 mg maintenance doses, aiming to identify optimal treatment protocols.
Why It Matters
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The evaluation of multiple dose levels and escalation schedules is crucial for optimizing future treatment regimens. This research is a critical step towards potentially bringing a new, potent weight-loss medication to clinical use, paving the way for larger Phase 3 human trials and regulatory approval.